August 21, 2013 – Tarrytown, New York. - PsychoGenics announced today that it has obtained an exclusive license from the University of South Florida to its APP/PS1 double transgenic mice (US Patent No. 5,898,094), co-expressing the M146L presenilin 1(PS1) mutation and the double mutations at K670N/M671L (Swedish mutation) in the amyloid precursor protein (APP). Read More.
June 17, 2013 – Tarrytown, New York. - PsychoGenics Inc. and Sunovion Pharmaceuticals Inc. announced that they have expanded the scope of their CNS drug discovery partnership and extended the agreement for another two years. Read More.